BIO-TECHNE Corp vs State Street Real Estate Select Sector SPDR ETF — how do they compare? BIO-TECHNE Corp trades at $72.45 (market cap $11.36B), while State Street Real Estate Select Sector SPDR ETF trades at $41.52 (market cap $7.61B). The key difference: BIO-TECHNE Corp is the larger of the two by market cap, and BIO-TECHNE Corp pays a 0.44% dividend while State Street Real Estate Select Sector SPDR ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold BIO-TECHNE Corp for 63 Days and State Street Real Estate Select Sector SPDR ETF for 75 Days on average.
| TECH | XLRE | |
|---|---|---|
Market Cap | $11.36B | $7.61B |
Volume | 5,390,331 | 7,876,569 |
Sector | Health | Sector/Thematic |
52-Week High | $72.61 | $46.01 |
52-Week Low | $43.31 | $40.01 |
Typical Hold Time | 63 Days | 75 Days |
Enterprise Value | $11.39B | — |
Dividend Yield | 0.44% | — |
Signals from Pluang's Aura AI — not financial advice
Bio-Techne (TECH) trades at $72.45, down 0.11% on the day, near its 52-week high of $72.70. The stock shows bullish technical signals with strong moving average support. Fundamentally, the company maintains solid gross margins of 65.77% but faces declining net income margins, dropping from 24.6% in 2022 to 6.01% in 2025. Recent shareholder approval of Merck KGaA's acquisition at $73 per share provides a clear near-term catalyst.
The pending acquisition offers limited upside from current levels but provides downside protection. However, declining profitability trends and elevated valuation ratios (P/E 62.46) pose risks if the deal falls through. Investors should weigh the acquisition premium against fundamental deterioration in earnings quality.
XLRE (Real Estate Select Sector SPDR ETF) trades at $41.21, up 1.58% with a bearish technical signal from moving averages. The ETF focuses on 30 U.S. large-cap real estate holdings with a low 0.08% expense ratio. Recent news highlights competition with global real estate ETFs and sector sensitivity to interest rate volatility. Technical indicators show mixed signals with RSI at neutral levels but ADX indicating strong bearish momentum.
The outlook remains cautious due to persistent interest rate pressures and sector rotation toward digital infrastructure. While offering cost-efficient real estate exposure, XLRE faces headwinds from elevated rates and AI-driven capital flows. Near-term performance depends on Federal Reserve policy clarity and real estate sector fundamentals.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →XLRE tracks the Real Estate Select Sector Index, providing exposure to S&P 500 real estate companies. It focuses on equity REITs across residential, industrial, and healthcare sub-sectors, with top holdings like Welltower, Prologis, and American Tower.
Read more on XLRE →